STOCK TITAN

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

MacroGenics (MGNX) reported third-quarter 2026 revenue of $18.667 million, down from the prior-year quarter, alongside progress across its cancer pipeline. Net loss was $20.076 million, versus net income of $16.822 million. Cash, cash equivalents and marketable securities reached $287.680 million at September 30, compared with $189.913 million at December 31, 2025. The company expects funding, including anticipated partner payments, to support operations through 2028.

MGC028 completed Phase 1 dose escalation; MacroGenics plans a two-dose randomized evaluation in its selected lead indication by year-end 2026. MGC030 entered Phase 1 dosing after clearance of its investigational application. Interim MGC026 and lorigerlimab results were presented at ESMO, with further updates expected in 2027. Third-quarter cash receipts included $119.6 million from the manufacturing operations sale to Bora, $24.5 million from Sanofi and $10.0 million from Gilead.

Loading...
Loading translation...
23 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 12 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointManufacturing operations sale to Bora provided $119.6 million in third-quarter cash consideration. 81% of market cap
  • Moderate pointCash and marketable securities rose to $287.680 million at September 30, 2026, from $189.913 million at year-end 2025.
  • Moderate pointSanofi regulatory milestone provided $24.5 million in third-quarter cash. 17% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Gilead exercised its preclinical bispecific license option, triggering $10.0 million; additional milestones and sales royalties remain possible. 6.8% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.MacroGenics expects cash and anticipated partner payments to support its runway through 2028.
  • Moderate pointThird-quarter royalty revenue increased to $8.582 million from $3.333 million a year earlier.
  • Moderate pointNine-month net loss narrowed to $37.335 million from $60.465 million; diluted loss per share narrowed to $0.58 from $0.96.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.MGC028 completed Phase 1 dose escalation; randomized testing of two doses is planned by year-end 2026.
15 minor points
  • Minor pointThird-quarter research and development expenses decreased to $30.610 million from $32.709 million a year earlier.
  • Minor pointThird-quarter general and administrative expenses decreased to $8.360 million from $9.905 million a year earlier.
  • Minor pointNine-month royalty revenue increased to $22.078 million from $5.087 million a year earlier.
  • Minor pointNine-month research and development expenses decreased to $104.363 million from $113.198 million a year earlier.
  • Minor pointNine-month general and administrative expenses decreased to $25.975 million from $29.925 million a year earlier.
  • Minor pointNine-month income from discontinued operations increased to $95.080 million from $15.464 million a year earlier.
  • Minor pointMGC028 had no dose-limiting toxicities, interstitial lung disease or ocular toxicity reported through October 10, 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.MGC028 interim efficacy and safety results in the selected lead indication are planned for first-half 2027.
  • Minor pointMGC026 interim Phase 1 results showed encouraging efficacy and manageable safety in heavily pretreated head-and-neck cancer, MacroGenics said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.MGC026 enrollment in its 40-patient head-and-neck cancer cohort is expected to finish by year-end 2026; updates are expected mid-2027.
  • Minor pointMGC030 reached first-patient dosing in Phase 1 following investigational application clearance.
  • Minor pointLorigerlimab showed encouraging preliminary Phase 2 activity in clear cell gynecologic cancer, MacroGenics said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Lorigerlimab enrollment of 20 patients at 3 mg/kg every three weeks is expected complete by year-end 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Lorigerlimab updated results are expected in first-half 2027.
  • Minor pointMGD032 is advancing through studies supporting an investigational drug application.

Negative

  • Moderate pointThird-quarter revenue fell to $18.667 million from $53.003 million a year earlier.
  • Moderate pointThird-quarter net results reversed to a $20.076 million loss from $16.822 million income a year earlier.
  • Moderate pointNine-month continuing-operations loss widened to $132.415 million from $75.929 million a year earlier.
  • Moderate pointStockholders' equity declined to $25.151 million at September 30, 2026, from $55.591 million at year-end 2025.
  • Minor pointThird-quarter diluted earnings reversed to a $0.32 loss per share from $0.27 income a year earlier.
7 minor points
  • Minor pointThird-quarter continuing operations reversed to a $21.475 million loss from $8.575 million income a year earlier.
  • Minor pointThird-quarter income from discontinued operations declined to $1.399 million from $8.247 million a year earlier.
  • Minor pointThird-quarter interest and other expense increased to $4.084 million from $3.342 million a year earlier.
  • Minor pointNine-month revenue fell to $58.220 million from $66.915 million a year earlier.
  • Minor pointNine-month royalty monetization liability extinguishment produced a $52.762 million loss, versus none a year earlier.
  • Minor pointNine-month interest and other expense increased to $13.369 million from $4.236 million a year earlier.
  • Minor pointCash runway guidance through 2028 includes projected and anticipated future partner payments, not existing cash alone.

Key Figures

Cash and marketable securities: $287.7 million Cash runway guidance: Through 2028 Total revenue: $18.7 million +5 more
Cash and marketable securities
$287.7 million
As of September 30, 2026; compared with $189.9 million at December 31, 2025
Cash runway guidance
Through 2028
Anticipated to be supported by cash and projected and anticipated future partner payments
Total revenue
$18.7 million
Q3 2026; compared with $53.0 million in Q3 2025
Net income (loss)
$20.1 million net loss
Q3 2026; compared with $16.8 million net income in Q3 2025
Bora sale cash consideration
$119.6 million
Received during the third quarter in connection with the sale of GMP manufacturing operations
Sanofi regulatory milestone
$24.5 million
Cash received during the third quarter
Gilead option license payment
$10.0 million
Payment triggered by Gilead's option exercise
Dose-limiting toxicities
0 reported
MGC028 as of the October 10, 2026 data cutoff

Previous Earnings Reports

2 past events · Latest: Aug 13
Same Type 2 events
  1. Aug 13

    Q2 2026 earnings

    24h Move
    +3.4%

    Reported pro forma cash of $327 million and estimated runway through 2028 after asset-sale and partner payments.

  2. May 13

    Q1 2026 earnings

    24h Move
    +20.6%

    Reported a Bora manufacturing sale agreement and projected cash runway through 2028.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

antibody-drug conjugate, t-cell engager, ild, investigational new drug, +1 more
5 terms
antibody-drug conjugate medical
"novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC)"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
t-cell engager medical
"T-cell engager (TCE)"
A T-cell engager is a type of medicine designed to help the body's immune system attack cancer cells more effectively. It works by acting like a bridge that brings immune cells (T-cells) close to cancer cells, prompting a targeted attack. For investors, T-cell engagers are significant because they represent innovative treatments that could lead to new growth opportunities in the healthcare and biotech sectors.
ild medical
"no cases of ILD or ocular toxicity were reported"
Interstitial lung disease (ILD) is a group of conditions that cause scarring and inflammation of the lung tissue responsible for moving oxygen into the bloodstream; think of it as the spongy part of the lungs becoming stiff and less able to stretch. For investors, ILD matters because it drives demand for diagnostic tests, treatments, and clinical trials, affects regulatory and safety profiles for drugs, and can influence the commercial outlook and risk profile of companies in respiratory and biotech sectors.
investigational new drug regulatory
"clearance of the Investigational New Drug (IND) application"
An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.
bispecific medical
"PD-1 × CTLA-4 bispecific DART® molecule"
A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels
  • Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients
  • First patient dosed with MGC030 in Phase 1 study
  • Strengthened Board with addition of two new independent directors with expertise in oncology drug discovery and development
  • Cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026; cash runway guidance remains through 2028

ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.

“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “We are grateful to our employees and partners for their dedication and contributions to this progress. Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”

Advancement of Innovative Pipeline

MacroGenics is developing a portfolio of investigational agents, including novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC), T-cell engager (TCE) and dual checkpoint inhibitor molecules.

  • MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. Phase 1 dose escalation of this molecule has been completed, and the Company has selected a lead indication. MacroGenics plans to initiate a randomized evaluation of two dose levels in this indication by year end 2026. As of a data cutoff of October 10, 2026, there were no dose-limiting toxicities, and no cases of ILD or ocular toxicity were reported. The Company intends to provide an interim clinical update, including efficacy and safety results in the lead indication, in the first half of 2027.

  • MGC026 is a novel ADC targeting B7-H3, a protein expressed across the tumor microenvironment, including tumor-associated stroma and vasculature. Interim Phase 1 results were reported at the European Society for Medical Oncology (ESMO) 2026 Congress (link), including encouraging efficacy data and a manageable safety and tolerability profile in heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients. The Company expects to complete enrollment of the ongoing 40-patient SCCHN Simon 2-stage monotherapy cohort by year end 2026, with updated data expected in mid-2027. In parallel, the Company will continue to evaluate the evolving competitive landscape and review the development and collaboration strategies for this molecule.

  • MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. Following clearance of the Investigational New Drug (IND) application, the first patient was dosed in a Phase 1 study in patients with advanced solid tumors, including urothelial, colorectal, gastric or gastroesophageal junction, esophageal and pancreatic cancers.

  • Lorigerlimab is a PD-1 × CTLA-4 bispecific DART® molecule being evaluated in patients with advanced gynecologic cancers. At ESMO 2026, the Company reported interim Phase 2 results (link) demonstrating encouraging preliminary clinical activity with single-agent lorigerlimab dosed at 6 mg/kg every three weeks (Q3W) in clear cell gynecologic cancer (CCGC). The Company expects to complete enrollment of 20 CCGC patients at a lower dose of 3 mg/kg Q3W by year end 2026, and report updated results in the first half of 2027.

Future Pipeline

MacroGenics is advancing multiple preclinical programs that incorporate proprietary platforms for next-generation TCEs and ADCs. MGD032, a novel next-generation TCE against an undisclosed target, is advancing in IND-enabling studies.

Corporate and Collaboration Updates

  • Appointment of New Independent Directors. In late October, MacroGenics appointed Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., two accomplished biopharmaceutical executives with extensive oncology drug development experience, to the Company’s Board of Directors. Drs. Kuriakose and Vasconcelles have established track records guiding innovative biotechnology companies through critical stages of growth and delivering substantial shareholder value.
  • Gilead Collaboration. On August 11, the Company announced that Gilead Sciences, Inc. had exercised its option to license a preclinical bispecific program under the companies’ 2022 collaboration agreement. This option exercise triggered a $10.0 million payment to MacroGenics. The Company remains eligible to earn additional milestones and royalties based on net product sales.

Third Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026, were $287.7 million, compared to $189.9 million as of December 31, 2025. During the third quarter, the Company received $119.6 million in cash consideration from Bora in connection with the sale of its GMP manufacturing operations, $24.5 million as regulatory milestone payment from Sanofi and $10.0 million option license payment from Gilead.
  • Revenue: Total revenue was $18.7 million for the quarter ended September 30, 2026, compared to $53.0 million for the quarter ended September 30, 2025. The decrease was primarily due to $50.0 million in milestone revenue recognized in 2025 under the Provention (Sanofi) Asset Purchase Agreement, compared to $10.0 million recognized in 2026 related to the option exercise under the Gilead Agreement, partially offset by a $5.3 million increase in ZYNYZ royalty revenue.
  • R&D Expenses: Research and development expenses were $30.6 million for the quarter ended September 30, 2026, compared to $32.7 million for the quarter ended September 30, 2025. The decrease was primarily due to lower costs related to lorigerlimab, vobramitamab duocarmazine, MGC030 manufacturing and IND-enabling activities, and certain preclinical ADCs, partially offset by increased costs related to MGC026, MGC028, MGC030 clinical activities and certain next-generation T-cell engagers.
  • G&A Expenses: General and administrative expenses were $8.4 million for the quarter ended September 30, 2026, compared to $9.9 million for the quarter ended September 30, 2025. The decrease was primarily due to lower personnel-related costs, including stock-based compensation expense.
  • Net Income (Loss): Net loss was $20.1 million for the quarter ended September 30, 2026, compared to net income of $16.8 million for the quarter ended September 30, 2025.
  • Shares Outstanding: Shares of common stock outstanding as of September 30, 2026, were 63,875,835.
  • Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, in addition to projected and anticipated future payments from partners, will support its cash runway through 2028.
MACROGENICS, INC.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(Amounts in thousands)
    
 September 30, 2026 December 31, 2025
 (unaudited)  
Cash, cash equivalents and marketable securities$287,680 $189,913
Total assets 318,685  256,846
Deferred revenue 55,503  56,779
Total stockholders' equity 25,151  55,591


MACROGENICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(Amounts in thousands, except share and per share data)
 
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2026   2025   2026   2025 
Revenues:       
Collaborative and other agreements$10,085  $49,670  $36,142  $61,828 
Royalty revenue 8,582   3,333   22,078   5,087 
Total revenues 18,667   53,003   58,220   66,915 
Costs and expenses:       
Research and development 30,610   32,709   104,363   113,198 
General and administrative 8,360   9,905   25,975   29,925 
Total costs and expenses 38,970   42,614   130,338   143,123 
Income (loss) from operations (20,303)  10,389   (72,118)  (76,208)
Loss on extinguishment of royalty monetization liability —   —   (52,762)  — 
Interest and other income 2,912   1,528   5,834   4,620 
Interest and other expense (4,084)  (3,342)  (13,369)  (4,236)
Income (loss) before income taxes (21,475)  8,575   (132,415)  (75,824)
Income tax provision —   —   —   105 
Net income (loss) from continuing operations (21,475)  8,575   (132,415)  (75,929)
Net income from discontinued operations, net of taxes 1,399   8,247   95,080   15,464 
Net income (loss) (20,076)  16,822   (37,335)  (60,465)
Other comprehensive income (loss):       
Unrealized gain (loss) on investments (293)  12   (340)  1 
Comprehensive income (loss)$(20,369) $16,834  $(37,675) $(60,464)
        
Net income (loss) per common share - basic       
Net income (loss) from continuing operations$(0.34) $0.14  $(2.08) $(1.21)
Net income from discontinued operations 0.02   0.13   1.50   0.25 
Net income (loss) per share - basic$(0.32) $0.27  $(0.58) $(0.96)
Net income (loss) per common share - diluted       
Net income (loss) from continuing operations$(0.34) $0.14  $(2.08) $(1.21)
Net income from discontinued operations 0.02   0.13   1.50   0.25 
Net income (loss) per share - diluted$(0.32) $0.27  $(0.58) $(0.96)
        
Weighted average common shares outstanding       
Basic 63,743,440   63,233,266   63,596,967   63,112,560 
Diluted 63,743,440   63,283,624   63,596,967   63,112,560 


About MacroGenics, Inc.


MacroGenics (the Company) is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com.MacroGenics, the MacroGenics logo and DART® are trademarks or registered trademarks of MacroGenics, Inc.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials, anticipated cash runway and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including our ability to execute on our key strategic priorities for 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks related to the reproducibility of any results initially seen in any product candidate; risks that any product candidate’s revenue, expenses and costs may not be as expected; risks relating to any product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data or clinical updates for any product candidates, including timing and results of efficacy and safety data with respect to any product candidates in ongoing clinical trials; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations regarding the expansion of ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; risks related to the transition of the CDMO operations to the purchaser following the sale of our CDMO operations; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

CONTACTS

Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were MacroGenics' third-quarter 2026 revenue and earnings?

MacroGenics reported $18.667 million in revenue and a $20.076 million net loss for the quarter ended September 30, 2026. The prior-year quarter had revenue of $53.003 million and net income of $16.822 million. Diluted results were a $0.32 loss per share versus $0.27 income per share.

How long does MacroGenics expect its cash to last?

MacroGenics expects its cash runway to extend through 2028, including projected and anticipated future payments from partners. Cash, cash equivalents and marketable securities totaled $287.680 million at September 30, 2026.

What doses is MacroGenics testing for lorigerlimab in clear cell gynecologic cancer?

The ongoing lower-dose cohort evaluates lorigerlimab at 3 mg/kg every three weeks, with enrollment of 20 patients expected to finish by year-end 2026. Interim Phase 2 results presented at ESMO evaluated single-agent lorigerlimab at 6 mg/kg every three weeks.

Why did MacroGenics' third-quarter 2026 revenue decline?

The decline primarily reflected $50.0 million in milestone revenue recognized in 2025 under the Provention (Sanofi) Asset Purchase Agreement, compared with $10.0 million recognized in 2026 for Gilead's option exercise. A $5.3 million increase in ZYNYZ royalty revenue partially offset that difference.

Keep reading